What does this research mean for the field?

In a real-world setting, mirvetuximab soravtansine provides clinically meaningful survival for patients with recurrent ovarian cancer, but overall survival is significantly shorter for those with an ECOG performance status greater than 1. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate real-world overall survival, progression-free survival, and toxicity associated with mirvetuximab soravtansine in patients treated for recurrent ovarian cancer.

September 3, 2026Gynecologic Oncology ReportsOpen Access

Real-world outcomes after Mirvetuximab Soravtansine treatment for recurrent ovarian Cancer: Results from a university setting

View Full Paper

Ask AI

Bookmark

Authors

AJAnna V. JonesWashington University in St. Louis RFRachel L FuruyaWashington University in St. Louis LML. Stewart MassadGynecologic Oncology Group

Discussion

Member takes

Implication

Retrospective study observes meaningful survival with mirvetuximab soravtansine in recurrent ovarian cancer, highlighting that baseline performance status strongly influences overall survival.

Key Points

To evaluate real-world overall survival, progression-free survival, and toxicity associated with mirvetuximab soravtansine in patients treated for recurrent ovarian cancer.
Retrospective review of N=66 patients with recurrent ovarian cancer treated with mirvetuximab soravtansine between November 2022 and April 2025 across an NCI-designated cancer center and an affiliated hospital.
Estimated progression-free survival and overall survival using Kaplan–Meier methods and identified prognostic clinical variables with multivariable Cox proportional hazards models.
Median overall survival reached 16.4 months (95% CI, 12.4 to NE) and median progression-free survival reached 5.3 months (95% CI, 4.1–7.1), with outcomes not differing significantly by platinum sensitivity status.
Patients with an ECOG performance status >1 exhibited significantly shorter median overall survival compared to those with a score of 0–1 (6.0 vs 20.3 months; P = 0.0006).
Treatment-related toxicities occurred in 91% of treated patients across the cohort.

Cite This Study

Jones et al. (2026) studied this question.

synapsesocial.com/papers/6a99352e636c6408cfa7d2ce https://doi.org/10.1016/j.gore.2026.102197

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study observes meaningful survival with mirvetuximab soravtansine in recurrent ovarian cancer, highlighting that baseline performance status strongly influences overall survival.

Real-world outcomes after Mirvetuximab Soravtansine treatment for recurrent ovarian Cancer: Results from a university setting

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world outcomes after Mirvetuximab Soravtansine treatment for recurrent ovarian Cancer: Results from a university setting

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider